LAG3 and melanoma: The combination of nivolumab with relatlimab (BMS-986016), an antibody directed against LAG3, has been shown to achieve an ORR of 16% in patients with advanced melanoma progressing after PD-1 or PD-L1 blockade [51]; relatlimab is being tested in a phase III trial (ClinicalTrials.gov Identifier: NCT03470922) [52].